Navigation Links
Sorafenib significantly improves the length of time before breast cancer worsens
Date:9/23/2009

Berlin, Germany: One of the first of a series of trials to investigate the use of sorafenib a targeted anti-cancer drug for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

Principal investigator of the study, Professor Jos Baselga told Europe's largest cancer congress, ECCO 15 ESMO 34 [1], in Berlin today (Wednesday 23 September): "This is the first, large, randomised study that demonstrates significant clinical activity of sorafenib in breast cancer when given in combination with chemotherapy. Our results showed that patients who received sorafenib plus capecitabine had a 74% percent improvement in the time they lived without their disease worsening compared to those who received the chemotherapy alone. This is a very positive study and the magnitude of the benefit is such that it suggests that this agent will be an important addition to our therapeutic armoury in breast cancer."

Sorafenib (Nexavar) is a potent multi-kinase inhibitor, which works by interfering with the growth of cancer cells and slowing the growth of new blood vessels within the tumour. Until now, it has only been used in the treatment of kidney and liver cancer.

Prof Baselga, who is head of the oncology department at Vall d'Hebron University Hospital (Barcelona, Spain), president of ESMO (European Society for Medical Oncology) and a member of the ECCO (European CanCer Organisation) executive committee, and his colleagues in Spain, France and Brazil enrolled 229 patients with locally advanced or metastatic breast cancer in the double-blind, randomised phase II clinical trial between June 2007 and December 2008. They randomised the patients to receive capecitabine (1000 mg/m2 pill taken twice daily for 14 of every 21 days) and a placebo (114 women), or capecitabine and sorafenib (400 mg pill taken twice daily
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Drug Sorafenib Improves Kidney Cancer Outcomes
2. Sorafenib Shows Promise for Heart-Lung Disease
3. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
4. Sorafenib Slows Growth of Some Leukemias
5. Women with atrial fibrillation are at significantly higher risk of stroke and death compared to men
6. Phoenix Children's Hospital Significantly Reduces Costs with Orion Health™ Technology
7. Radiologists find a technique to significantly reduce patient radiation dose during CT angiography
8. New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated
9. African Americans at Significantly Higher Risk of DVT or Blood Clots
10. Significantly Higher Percentage of Hetastarch Recipients Underwent a Surgical Procedure Than Those Receiving Albumin/Plasma Protein Fraction
11. New Data Show ChloraPrep(R) Significantly More Effective Than DuraPrep(TM) and Povidone-Iodine in Eliminating Bacteria From Skin Prior to Shoulder Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... life. The last stage, when two daughter cells split ... of cell biology in the Victorian era. For just ... this final step, when the dividing cell creates a ... to this process by those early biologists, cytokinesis, translates ... highly active and organized series of events. Scientists have ...
(Date:10/31/2014)... (PRCHN) at Case Western Reserve University School of ... million in federal grants awarded to improve community ... Disease Control and Prevention (CDC) renewed the PRCHN,s ... funds will support the center,s ongoing efforts in ... interventions that prevent and reduce chronic disease in ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review ... fat loss program ever developed. It promises to provide users ... is no wonder after all that this has become the ... nutrition and workout fat loss program was created by Joel ... to the author of this fat loss system, the method ...
(Date:10/31/2014)... At the start of 2014, numerous ... carbon monoxide poisoning in their homes. Now, as 2015 ... family-owned, Missouri-based heating and cooling company is taking a ... start the home heating season with the assurance that ... Beginning Nov. 1, 2014, E and Q Heating and ...
(Date:10/31/2014)... 2014 Energy Textiles has recently added ... gear is now available online, and Energy Textile is ... Celliant infrared-active athletic gear over compression gear. , ... has been signed for Under Armour to provide team ... eight years. In light of this decision, Energy Textiles ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4
... care enhancement program for patients with multiple chronic ... patient/family communications and their knowledge of their patients, ... at the Johns Hopkins Bloomberg School of Public ... of Annals of Family Medicine , found ...
... NY JULY 20, 2010 TCT 2010 (Transcatheter ... technologies and practices in interventional cardiology that will directly ... (September 21-25 in Washington, DC), late breaking data from ... cardiology techniques, and the interactions and effectiveness of new ...
... during and after pregnancy were able to cut the incidence ... study published in the British Journal of Dermatology ... at the Norwegian University of Science and Technology (NTNU), compared ... to women who were given a placebo. Use of the ...
... Reinberg HealthDay Reporter , MONDAY, July 19 (HealthDay ... of developing persistent ringing in the ear -- a condition ... one U.S. ear specialist called the data used for the ... a connection between cell phone use and tinnitus. The ...
... , MONDAY, July 19 (HealthDay News) -- People in an Alabama ... in their bodies were much more likely to have high blood ... PCBs actually caused their hypertension. If a direct connection does ... exposed to PCBs, which were once used in many products but ...
... in HIV/AIDS (BC-CfE) published an important study today in ... reinforces the view that the benefits of highly active ... to significantly preventing the transmission and spread of HIV. ... HIV, HAART uses a combination of drugs to stop ...
Cached Medicine News:Health News:Guided Care improves physician satisfaction with patient/family communications 2Health News:TCT 2010 to have significant impact on interventional cardiology practices and patient care 2Health News:Probiotics use in mothers limits eczema in their babies 2Health News:Can Cell Phones Cause Another Kind of Ringing? 2Health News:Could PCBs Help Boost Blood Pressure? 2Health News:Could PCBs Help Boost Blood Pressure? 3Health News:HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study 2Health News:HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study 3
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... , October 31, 2014 ... Inc. (NASDAQ: NSPH ), Isis Pharmaceuticals Inc. ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... 30, 2014, the NASDAQ Composite ended at 4,566.14, up ...
(Date:10/31/2014)... British Journal of Urology ... discuss "male orgasmic dysfunction" with their doctor prior to ... symptoms while preserving sexual function     ... a paper in the British Journal of Urology International ... discuss with their doctors the likely impact of treatment ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2
... Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or ... September 30, 2009. All figures included herein were prepared ... Mexican pesos. Also, the following consolidated figures show the Company,s ... , 3Q09 Highlights (vs. 3Q08) , During ...
... 26 ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer ... announced that it will release financial results for the third ... Monday, November 2, 2009. The Company will host a ... 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss ...
Cached Medicine Technology:Genomma Lab Internacional Announces Third Quarter 2009 Results 2Genomma Lab Internacional Announces Third Quarter 2009 Results 3ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call 2
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Medicine Products: